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We appreciate the interest of Dr. Rahimtoola in our study of
pulmonary hypertension in patients with aortic stenosis (1), and we
appreciate his comments underscoring the importance of the data.
Unfortunately, it was not possible to present all the data we
collected as space is limited by the Journal. Below are the responses
to the specific queries made:
1. Left ventricular ejection fraction was derived by two-
dimensional echocardiography using visual estimate in all pa-
tients and combining it to M-mode measurements in 23
patients (49%). This approach has been proven in previous
studies to be highly predictive of outcome, at least as well as
angiography (2).
2. The mean  SD (range) Doppler-derived calculations of the
pulmonary artery systolic pressure (PASP) assuming a mean
right atrial pressure of 10 mm Hg were:
79.5  8.0 mm Hg (74–106) for the entire group
82.0  11.6 mm Hg (74–106) for the No-AVR (aortic
value replacement) group
78.8  6.8 mm Hg (74–102) for the AVR group
These data confirm, irrespective of the estimated right atrial
pressure, that the pulmonary hypertension in our study population
was indeed severe.
3. With regard to coronary disease, 34 patients (72%) underwent
selective coronary angiography—AVR group, 32 patients
(86%); No-AVR group, 2 patients (20%). These rates are well
expected, as the small but definite risk of coronary angiography
is not warranted in patients who either refuse surgery or are not
considered candidates for surgery.
A total of 19 patients had initially unprotected obstructive
coronary artery disease—17 among the AVR-group patients, all of
whom underwent coronary artery bypass graft surgery (CABG).
The remaining 15 patients (all in the AVR group) had either
normal or minimally diseased coronary arteries (12 patients) or
patent grafts from prior CABG (3 patients). The five-year survival
rate of AVR patients who underwent CABG (58%, SE 0.16) was
not significantly different (p  0.87) from that of AVR patients
without obstructive coronary disease on angiography, including
those with previous bypass and patent grafts (48%, SE 0.18).
Moreover, there was no significant difference in the severity of
pulmonary hypertension between these two AVR subgroups
(PASP 78.4  4.8 mm Hg [74–87] for isolated AVR patients vs.
79.6  8.7 mm Hg (74–102) for AVR patients who needed
CABG; p  0.9). This suggests that the poor outcome in this
subset of patients is indeed the result of pulmonary hypertension
rather than that of coronary disease.
4. The five-year survival (mean  SE) for AVR patients, includ-
ing operative mortality, was 48  12%; the p value in compar-
ison to expected survival was 0.0001. Indeed, despite treat-
ment, this group is at high risk, although less than historical
controls with similar levels of pulmonary hypertension but no
aortic stenosis (AS) (3). Hence, an important conclusion of our
study is that it is essential that patients be operated on before
they reach such a considerable level of pulmonary hypertension.
Nevertheless, as operative results continuously improve, the
postoperative survival excluding operative mortality, in our
mind, is also important and supports hope of a better outcome
for patients with AS and severe pulmonary hypertension who
otherwise are at very high risk.
We appreciate the interest of Dr. Rahimtoola, which allows
underscoring further the importance of detecting pulmonary hy-
pertension in patients with aortic stenosis.
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Coronary Atherosclerosis
and Body Iron Stores
We read with great interest the study by Gaenzer et al. (1) in a
recent issue of the Journal. The investigators studied associations
between iron status and early functional and structural vascular
abnormalities in patients with hereditary hemochromatosis and
found that impaired endothelial function and increased intima-
media thickness (IMT) may be associated with iron overload, with
subsequent induction of oxidative stress. Gaenzer and colleagues
suggested that iron-depletion therapy, which normalizes endothe-
lial function, may reduce the increased risk of cardiovascular
events.
A possible association between body iron status and the risk of
coronary heart disease was first supported by findings from a
Finnish study relating increased levels of both serum ferritin and
dietary iron to an increased risk of myocardial infarction in men
(2). It is believed that inflammation and oxidation are important
mechanisms involved in the complex pathological process of
atherogenesis (3). Free radical production is catalyzed and accel-
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erated in the presence of iron (4) and this has been used as a
possible explanation for the higher incidence of ischemic heart
disease in young and middle-aged men compared to premeno-
pausal women, as ferritin concentrations are three times higher in
men than in premenopausal women (5). In contrast, more recently
published data, like the studies by Aronow (6), Moore et al. (7),
and Ascherio and colleagues (8), do not support the hypothesis of
a relationship between serum ferritin and atherosclerosis risk.
It is noteworthy that the putative role of iron in the develop-
ment of atherosclerosis is based primarily on clinical and epidemi-
ological studies. However, only few reports investigating correla-
tions between serum concentration of ferritin and anatomic
diagnosis of coronary atherosclerosis assessed by coronary arteriog-
raphy are available in the published data. We (9) could recently
demonstrate that, in patients referred for coronary angiography,
higher ferritin concentrations and transferrin-saturation levels (as
measures of the amount of circulating iron available to tissues) are
not associated with an increased extent of coronary atherosclerosis
(as assessed angiographically). In that study (9), estimates of the
relative risk of coronary heart disease for the quintile with the
highest concentration of serum ferritin as compared with the
lowest quintile were 0.83 (95% confidence interval, 0.63 to 1.24).
Another important point seems to be that all the iron indicators
used to relate iron status to coronary artery disease (CAD) are
affected by inflammation. As a result, an association between CAD
and higher serum ferritin levels could be confounded by inflam-
mation (10). A shortcoming of the study by Gaenzer et el. (1) is
the lack of information on inflammatory markers such as
C-reactive protein.
In summary, early functional and structural vascular abnormal-
ities in patients with hereditary hemochromatosis may predict both
extent of coronary atherosclerosis and the risk of cardiovascular
events in this particular patient group, but in subjects without
hereditary hemochromatosis our results and data from others do
not support the hypothesis that body iron stores, as measured by
serum ferritin and transferrin saturation, are related to the risk of
CAD. In patients with hereditary hemochromatosis, enhancement
of atherogenesis may involve additional mechanisms beyond iron.
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REPLY
We agree with Dr. Auer and colleagues that ferritin levels in our
study (1) may be both a reflection of increased iron stores linked to
primary iron overload and an indication of a chronic inflammation,
as ferritin expression is also regulated by inflammatory cytokines
(2,3).
To rule out the possibility that increased ferritin levels in
hemochromatotic patients are a reflection of an ongoing inflam-
matory response we performed conventional serum tests for
C-reactive protein (CRP), which were all normal in the hemo-
chromatotic subjects included in our study. However, we cannot
rule out that by using a high-sensitive CRP assay we could have
found low-grade inflammation not detected by the conventional
test (4), which would have been of interest because, at least in
diabetics, elevated levels of CRP have been associated with early
structural changes of arteries (5) and because iron is known to
increase formation of hydroxyl radicals during an inflammatory
process (6), which will then exert harmful effects toward the
endothelium.
However, in our study, changes in endothelial-dependent dila-
tion (EDD) very well correlated with transferrin saturation in a
way that higher transferin saturation (TfS) was associated with
increased oxidative stress, increased intima-media thickness, and
decreased EDD. This observation argues against an important role
of inflammation in our setting. This notion is based on the fact
that, during inflammation, drastic changes in iron homeostasis and
distribution occur, which frequently lead to the development of
anemia of chronic disease (7). This condition is characterized by
high ferritin levels and low transferrin saturation, the later just
being the opposite of what is observed in hemochromatotic
patients, even in our study.
Finally, our data demonstrate a close relationship among iron
overload, impaired EDD, and increased intima-media thickness,
which may not be primarily referred to an underlying inflammatory
condition. Nonetheless, determination of high-sensitive CRP will
be attractive to see whether iron overload may induce low-grade
inflammation in hemochromatotic patients.
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